To accelerate a cure for each and every multiple myeloma patient.
The Multiple Myeloma Research Foundation Inc concentrates its funding on multiple myeloma research infrastructure, with a pattern of large site investment grants to major cancer centers and medical schools. Its recent grant history shows repeated support for immunotherapy, prevention, translational core work, and fellowships tied to clinical and laboratory research. The largest recent grant in the data is $2,804,526 to Dana-Farber Cancer Institute for site investment, immunotherapy, and prevention, and the same institution appears again with a $1,050,000 grant in 2024 and a $1,000,000 grant in 2025. Icahn School of Medicine at Mount Sinai also appears multiple times, including a $1,964,644 grant in 2024 and a $1,900,000 grant in 2025. Beyond the biggest awards, the foundation backs a mix of research institutions, clinical trial sites, and early-career researchers through programs such as the MMRF Scholars Program and the MMRF Research Fellowship Program. The stated summary goal is to accelerate a cure for each and every multiple myeloma patient.
Immunotherapy is one of the clearest themes in the grant record. The foundation gave $860,550 to Beth Israel Deaconess Medical Center in 2025 for site investment and immunotherapy, and it also supported Washington University in St. Louis with $806,802 in 2024 for the same broad area. Prevention appears alongside research funding as well: Dana-Farber Cancer Institute received $1,000,000 in 2025 for site investment and prevention. Translational support is visible at Memorial Sloan-Kettering Cancer Center, which received $100,000 in 2024 for site investment, fellow, translational core, and prevention. Early-career support is also explicit in grants to Emory University and The University of Chicago, both tagged with fellow in the recent-grants list.
Typical grant sizes sit in a mid-six-figure to low-six-figure range: p25 is $27,500, median is $66,250, and p75 is $135,000. The recent record also shows several multi-year relationships rather than one-off awards, including Dana-Farber Cancer Institute, Icahn School of Medicine at Mount Sinai, Beth Israel Deaconess Medical Center, Emory University, and UCSF Myeloma Research Program. The foundation makes program-related investments and runs at least two open U.S. programs that accept unsolicited applications: the MMRF Scholars Program and the MMRF Research Fellowship Program. The Scholars Program supports clinical, translational, or basic science projects, while the Fellowship Program is a fixed $150,000 award.
$4.8M
$66.4M
$29.1M
$35.6M
Most grants fall between $28K and $135K, with a median of $66K.
25th Percentile
$28K
Median
$66K
75th Percentile
$135K
About 0% of grants go to recipients in MA.
MICHAEL ANDREINI
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Grantmaking is national in scope, and every grant in the provided recent list went to a U.S. recipient. The highest concentration of grants lands in Minnesota, even though the foundation is headquartered in Norwalk, Connecticut and none of the recent grants went to Connecticut recipients. Recent awards cluster in Boston, New York, and San Francisco, with additional grants in Atlanta, St. Louis, Rochester, Dallas, Chicago, and Newark-area institutions such as Hackensack. Outside the U.S., no recipient countries appear in the data.
The recent grants go to research institutions, medical schools, cancer centers, and clinical trial sites, including Dana-Farber Cancer Institute, Icahn School of Medicine at Mount Sinai, Beth Israel Deaconess Medical Center, and UCSF Myeloma Research Program. The foundation also supports early-career researchers through fellow-tagged grants.
The active program and grant tags point to multiple myeloma research, clinical trials, precision and personalized medicine, genomic and translational data, immunotherapy research, patient education and support, and health equity and access. In the recent-grants list, immunotherapy and prevention appear repeatedly alongside site investment grants.
Yes for at least two active U.S. programs. The MMRF Scholars Program accepts unsolicited applications, and the MMRF Research Fellowship Program also accepts unsolicited applications. The Myeloma Accelerator Challenge is listed as a funding opportunity, but it is marked as not accepting unsolicited applications in the provided data.
The grant-size distribution centers on smaller awards than the largest site investments suggest: p25 is $27,500, the median is $66,250, and p75 is $135,000. The active Scholars Program is larger, at $100,000 to $400,000, while the Research Fellowship Program is a fixed $150,000 award.
Yes. Several organizations appear in multiple years, including Dana-Farber Cancer Institute, Icahn School of Medicine at Mount Sinai, Beth Israel Deaconess Medical Center, Emory University, and UCSF Myeloma Research Program. That pattern suggests sustained site-based support rather than isolated one-time awards.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Current and upcoming funding from Multiple Myeloma Research Foundation that your nonprofit may be able to apply for.
Who can apply: Applications may be submitted by investigators from academic and non-profit institutions worldwide. For-profit entities are not eligible to apply through this RFA.
Deadline: Cycle 1: September 15, 2026; Cycle 2: December 15, 2026; Cycle 3: March 15, 2027
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $1,900,000 | 2025 | SITE INVESTMENT GRANT, IMMUNOTHERAPY, MYELOMA ACCELERATOR CHALLENGE GRANT |
| DANA FARBER CANCER INSTITUTE | BOSTON, MA | $1,000,000 | 2025 | SITE INVESTMENT GRANT, PREVENTION |
| BETH ISRAEL DEACONESS MEDICAL CENTER | BOSTON, MA | $860,550 | 2025 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| EMORY UNIVERSITY | ATLANTA, GA | $563,000 | 2025 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| CITY OF HOPE | DURATE, CA | $105,000 | 2025 | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY |
| UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER | DALLAS, TX | $60,000 | 2025 | FELLOW |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $60,000 | 2025 | IMMUNOTHERAPY |
| OHIO STATE UNIVERSITY RESEARCH FOUNDATION | COLUMBUS, OH | $30,000 | 2025 | FELLOW |
| HACKENSACK UNIVERSITY MEDICAL CENTER | HACKENSACK, NJ | $25,000 | 2025 | SITE INVESTMENT GRANT |
| BARBARA ANN KARMANOS CANCER HOSPITAL | DETROIT, MI | $25,000 | 2025 | SITE INVESTMENT GRANT |
| TENNESSEE ONCOLOGY PLLC | NASHVILLE, TN | $25,000 | 2025 | SITE INVESTMENT GRANT |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $25,000 | 2025 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| THE UNIVERSITY OF CHICAGO | CHICAGO, IL | $25,000 | 2025 | SITE INVESTMENT GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $25,000 | 2025 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NEW YORK, NY | $25,000 | 2025 | SITE INVESTMENT GRANT |
| BE THE MATCH FOUNDATION | MINNEAPOLIS, MN | $10,000 | 2025 | IMMUNOTHERAPY |
| INDIANA UNIVERSITY | BLOOMINGTON, IN | $7,500 | 2025 | FELLOW |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $1,964,644 | 2024 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| DANA FARBER CANCER INSTITUTE | BOSTON, MA | $1,050,000 | 2024 | SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $806,802 | 2024 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| EMORY UNIVERSITY | ATLANTA, GA | $613,060 | 2024 | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION |
| BETH ISRAEL DEACONESS MEDICAL CENTER | BOSTON, MA | $612,829 | 2024 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| MAYO CLINIC - ROCHESTER | ROCHESTER, MN | $405,695 | 2024 | SITE INVESTMENT GRANT |
| UCSF MYELOMA RESEARCH PROGRAM | SAN FRANCISCO, CA | $150,000 | 2024 | SITE INVESTMENT GRANT |
| CITY OF HOPE | DURATE, CA | $130,000 | 2024 | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY |
| UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER | DALLAS, TX | $110,000 | 2024 | SITE INVESTMENT GRANT |
| HACKENSACK UNIVERSITY MEDICAL CENTER | HACKENSACK, NJ | $101,729 | 2024 | SITE INVESTMENT GRANT |
| SARAH CANNON RESEARCH INSTITUTE LLC | NASHVILLE, TN | $100,000 | 2024 | SITE INVESTMENT GRANT |
| BARBARA ANN KARMANOS CANCER HOSPITAL | DETROIT, MI | $100,000 | 2024 | SITE INVESTMENT GRANT |
| THE UNIVERSITY OF CHICAGO | CHICAGO, IL | $100,000 | 2024 | SITE INVESTMENT GRANT, FELLOW |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NEW YORK, NY | $100,000 | 2024 | SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $60,000 | 2024 | IMMUNOTHERAPY |
| OHIO STATE UNIVERSITY RESEARCH FOUNDATION | COLUMBUS, OH | $55,000 | 2024 | SITE INVESTMENT GRANT |
| LEVINE CANCER CENTER | CHARLOTTE, NC | $50,000 | 2024 | SITE INVESTMENT GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $42,500 | 2024 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $25,000 | 2024 | SITE INVESTMENT GRANT |
| BE THE MATCH FOUNDATION | MINNEAPOLIS, MN | $10,000 | 2024 | IMMUNOTHERAPY |
| INDIANA UNIVERSITY | BLOOMINGTON, IN | $7,500 | 2024 | FELLOW |
| DANA FARBER CANCER INSTITUTE | BOSTON, MA | $2,804,526 | 2023 | SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION |
| BETH ISRAEL DEACONESS MEDICAL CENTER | BOSTON, MA | $632,000 | 2023 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $363,019 | 2023 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
| EMORY UNIVERSITY | ATLANTA, GA | $110,700 | 2023 | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION |
| THE UNIVERSITY OF CHICAGO | CHICAGO, IL | $86,996 | 2023 | SITE INVESTMENT GRANT, FELLOW |
| INDIANA UNIVERSITY | BLOOMINGTON, IN | $67,500 | 2023 | FELLOW |
| UCSF MYELOMA RESEARCH PROGRAM | SAN FRANCISCO, CA | $65,000 | 2023 | SITE INVESTMENT GRANT |
| OHIO STATE UNIVERSITY RESEARCH FOUNDATION | COLUMBUS, OH | $62,500 | 2023 | SITE INVESTMENT GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NEW YORK, NY | $62,500 | 2023 | SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION |
| BARBARA ANN KARMANOS CANCER HOSPITAL | DETROIT, MI | $30,000 | 2023 | SITE INVESTMENT GRANT |
| H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE | TAMPA, FL | $30,000 | 2023 | FELLOW |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $27,500 | 2023 | SITE INVESTMENT GRANT, IMMUNOTHERAPY |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
$1,900,000SITE INVESTMENT GRANT, IMMUNOTHERAPY, MYELOMA ACCELERATOR CHALLENGE GRANT
SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY
UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER
$60,000FELLOW
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$60,000IMMUNOTHERAPY
OHIO STATE UNIVERSITY RESEARCH FOUNDATION
$30,000FELLOW
HACKENSACK UNIVERSITY MEDICAL CENTER
$25,000SITE INVESTMENT GRANT
BARBARA ANN KARMANOS CANCER HOSPITAL
$25,000SITE INVESTMENT GRANT
TENNESSEE ONCOLOGY PLLC
$25,000SITE INVESTMENT GRANT
MASSACHUSETTS GENERAL HOSPITAL
$25,000SITE INVESTMENT GRANT, IMMUNOTHERAPY
MEMORIAL SLOAN-KETTERING CANCER CENTER
$25,000SITE INVESTMENT GRANT
INDIANA UNIVERSITY
$7,500FELLOW
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
$1,964,644SITE INVESTMENT GRANT, IMMUNOTHERAPY
SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION
UCSF MYELOMA RESEARCH PROGRAM
$150,000SITE INVESTMENT GRANT
UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER
$110,000SITE INVESTMENT GRANT
HACKENSACK UNIVERSITY MEDICAL CENTER
$101,729SITE INVESTMENT GRANT
SARAH CANNON RESEARCH INSTITUTE LLC
$100,000SITE INVESTMENT GRANT
BARBARA ANN KARMANOS CANCER HOSPITAL
$100,000SITE INVESTMENT GRANT
MEMORIAL SLOAN-KETTERING CANCER CENTER
$100,000SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$60,000IMMUNOTHERAPY
OHIO STATE UNIVERSITY RESEARCH FOUNDATION
$55,000SITE INVESTMENT GRANT
LEVINE CANCER CENTER
$50,000SITE INVESTMENT GRANT
MASSACHUSETTS GENERAL HOSPITAL
$42,500SITE INVESTMENT GRANT, IMMUNOTHERAPY
UNIVERSITY OF MICHIGAN
$25,000SITE INVESTMENT GRANT
INDIANA UNIVERSITY
$7,500FELLOW
SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION
INDIANA UNIVERSITY
$67,500FELLOW
UCSF MYELOMA RESEARCH PROGRAM
$65,000SITE INVESTMENT GRANT
OHIO STATE UNIVERSITY RESEARCH FOUNDATION
$62,500SITE INVESTMENT GRANT
MEMORIAL SLOAN-KETTERING CANCER CENTER
$62,500SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION
BARBARA ANN KARMANOS CANCER HOSPITAL
$30,000SITE INVESTMENT GRANT